KIT and chronic myelogenous leukemia, BCR-ABL1 positive: This tyrosine-inhibitory compound has been successful in targeting KIT mutations and related genetic aberrations in gastrointestinal stromal tumor (GIST), chronic myeloid leukemia and other c-kit expressing tumors.